Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Kymera Therapeutics (KYMR) and increased the price target from $39 to $56.
February 27, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reaffirmed its Overweight rating on Kymera Therapeutics and raised the price target from $39 to $56.
The increase in price target by a reputable analyst firm like Piper Sandler typically signals a strong bullish outlook on the stock, suggesting potential upside. This could lead to increased investor confidence and a possible short-term price increase for KYMR.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100